Literature DB >> 3524366

The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study.

H Eule, A Weinecke, I Roth, H Wuthe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3524366     DOI： 10.1111/j.1749-6632.1986.tb18548.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  8 in total

1.  British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.

Authors:  G J Gibson; R J Prescott; M F Muers; W G Middleton; D N Mitchell; C K Connolly; B D Harrison
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

Review 2.  Current concepts in the management of sarcoidosis.

Authors:  M M Muthiah; J T Macfarlane
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 3.  Corticosteroids for pulmonary sarcoidosis.

Authors:  N S Paramothayan; T J Lasserson; P W Jones
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 4.  Nonpulmonary manifestations of sarcoidosis.

Authors:  Stephen J Oliver
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 5.  Clinical and immunologic components of sarcoidosis.

Authors:  Andrea T Borchers; Calvin So; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

Review 6.  Advances in the diagnosis and treatment of sarcoidosis.

Authors:  Marc A Judson
Journal:  F1000Prime Rep       Date:  2014-10-01

Review 7.  Current and emerging pharmacological treatments for sarcoidosis: a review.

Authors:  Scott H Beegle; Kerry Barba; Romel Gobunsuy; Marc A Judson
Journal:  Drug Des Devel Ther       Date:  2013-04-12       Impact factor: 4.162

8.  Role of serum immunoglobulins for predicting sarcoidosis outcome: A cohort study.

Authors:  Nicolas Belhomme; Stéphane Jouneau; Guillaume Bouzillé; Olivier Decaux; Mathieu Lederlin; Stéphanie Guillot; Antoinette Perlat; Patrick Jégo
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.